October 18, 2018

Gaithersburg, MD — VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates to a virus-like particle vaccine comprising flavivirus structural proteins to prevent or treat flavivirus infection. Flavivirus includes dengue virus, West Nile virus, Japanese encephalitis, hepatitis C virus, and Zika virus.

Wataru Akahata, CEO of VLP Therapeutics commented, “The issuance of this patent is a significant step in being able to protect our unique tetravalent dengue vaccine. We have recently generated encouraging data indicating that our dengue vaccine is safe and effective in nonhuman primates. We hope to initiate process development and manufacturing for our dengue vaccine to enable filing of an IND in 2020.” US Patent 10,098,943 is VLP Therapeutics’ fifth issued US Patent and adds to a patent portfolio covering composition of matter and methods of using the Company’s virus like particle technology.  

Dengue fever is a mosquito-borne disease caused by the flavivirus and has spread to most tropical and many subtropical areas. There is no effective dengue vaccine or therapeutic and prevention against dengue fever is currently limited to vector control measures. A dengue vaccine would therefore represent a major advance in the control of the disease.  

While several dengue vaccine candidates are currently being evaluated in clinical studies, VLP Therapeutics believes that a virus-like particle dengue vaccine would have a broader therapeutic window than live attenuated vaccines, thus allowing it to be administered to infants and pregnant women.  

About VLP Therapeutics

VLP Therapeutics was established in 2013 by a group of seasoned entrepreneurs based upon a novel, proprietary vaccine technology discovered by its co-founder Dr. Wataru Akahata, PhD. The Company’s mission is to create next-generation virus-like particles to transform traditional vaccine therapies and combat the 21st century global public health problems. VLP Therapeutics is currently developing vaccines to treat cancer and infectious diseases such as Malaria and Dengue fever

Our virus-like particles have proven to be highly immunogenic in multiple animal models and we anticipate our malaria vaccine entering a phase 1/2a human trial in 2018. The company is headquartered in Gaithersburg, Maryland.

More information about VLP Therapeutics can be found at www.VLPTherapeutics.com. Information may also be obtained by contacting VLP Therapeutics at:

VLP Therapeutics

Jacob Licht